NOVEL HUMAN ENDOGENOUS RETROVIRAL ERV3 VARIANT AND USES THEREOF IN THE DIAGNOSING OVARIAN CANCER
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Nov 24, 2011
app pub date -
Dec 23, 2008
filing date -
Dec 9, 2008
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The present invention relates to polynucleotide and polypeptide sequences of a novel human endogenous retroviral ERV3 variant which is differentially expressed in ovarian cancer cells when compared to normal cells. The present invention more particularly relates to the use of these polynucleotide and polypeptide in the diagnosis, prognosis or treatment of cancer and in the detection of cancer cells.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully